Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Escobar, Giulia ^a   Gentner, Bernhard ^a   Naldini, Luigi ^a   Mazzieri, Roberta ^b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Breast cancer; Gene transfer strategy; IFN delivery; Immunosuppressive microenvironment; Tumour associated macrophages

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 7;

ADAPTIVE IMMUNITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ENGINEERING; CYTOKINE RELEASE; DNA MODIFICATION; DRUG EFFICACY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; IFN ALPHA GENE; IMMUNOPOTENTIATION; IMMUNOREACTIVITY; INNATE IMMUNITY; LYMPHOCYTE HOMING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84902596900     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28696     Document Type: Article

References (10)

1. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211-26; PMID:16169466; http://dx.doi. org/10.1016/j.ccr.2005.08.002
2. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186:4183-90; PMID:21368233; http://dx.doi.org/10.4049/jimmunol.1002802
3. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19:512-26; PMID:21481792; http://dx.doi.org/10.1016/j.ccr.2011.02.005
4. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9; PMID:15951814; http://dx.doi. org/10.1038/ni1213
5. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14:299-311; PMID:18835032; http://dx.doi.org/10.1016/j. ccr.2008.09.004
6. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458:904-8; PMID:19212321; http:// dx.doi.org/10.1038/nature07815
7. Ibberson M, Bron S, Guex N, Faes-van't Hull E, Ifticene-Treboux A, Henry L, Lehr HA, Delaloye JF, Coukos G, Xenarios I, et al. TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clin Cancer Res 2013; 19:3439-49; PMID:23649001; http://dx.doi.org/10.1158/1078-0432.CCR-12-3181
8. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012; 18:1224-31; PMID:22820642; http://dx.doi.org/10.1038/ nm.2830
9. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207:2053-63; PMID:20837696; http:// dx.doi.org/10.1084/jem.20101664
10. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014; 25:37-48; PMID:24434209; http://dx.doi. org/10.1016/j.ccr.2013.12.004